We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I'm a mere 80% down. Long way to go before I start getting excited by this share again - they need to start delivering, with ink drying on contracts. Significant potential, but far too many disappointments.
Me Too, 92.38% down but still have hope
Snap, joey !
Come on Rene, only 92% down!!!
For no reason, LOL. Did you not watch the IM presentation? Have you not seen the Director buys?
Sudden signs of SP awakening at last, for apparently no reason.
If you re-listen to the recent investor call IR talks about data that is coming out & he certainly sounds confident. Add to that the Director purchases we have seen then we can rightly come to the conclusion the data they are seeing is very positive.
If they produce groundbreaking data then interest in commercial deals will accelerate.
Noise about the need for a capital raise is just that (noise). Yes they will need a capital raise next year, but the company producing solid data in 2023 would more likely lead to upfront payments structured deals.
I thought that as well. Good also to see that NED purchase. Good weekend all.
I think him not buying the extra £20k is a positive thing in that it vaguely implies he expects the company to do well because then the rise in share price would be its own reward, rather than cutting and running off with the £175k bonus. Just a guess.
Just noticed I wrote my last post in the wrong tense - but the concept still stands :)
Anyway, another purchase by Iain. He continues to retain my full backing and faith. Good weekend all.
The loss of two major shareholders within six months seems, at best, unfortunate, with the last beginning to dump shares in March.
Hopefully it is for reasons of integrity. Although, he could still buy another 20K (or more) and in that RNS Director Purchase, it could be noted that he does not intend to claim the bonus, until X share price is reached, or at least one deal signed and delivered etc.
Anyway, just a watching game here for me at this point. Not adding, but not selling either. GLA.
He will not get the £175K bonus as he had to spend £75K in purchasing shares before March 2023. He spent £55K and only needed to spend another £20K to claim the £175K bonus. So the question is why didn't he.
The annual report issued today gives us the actual reason why Iain bought 400,000 shares. On page 40 the notes state that his £175k bonus is dependent on him using £75k of it in buying Reneuron shares. He has spent £55,838 so far (see p77). So he could "buy" around 250,000 more at current prices, give or take. I don't consider this as a vote of confidence by a director if his hand is forced, even if he does sound enthusiastic. I say back your company with YOUR savings like us shareholders...then I just might trust what you say.
FYI his share options, 750,000 in total, are triggered at 10p/31p/50p with no link to performance. Nice. DYOR.
management motto u play ball with me and i will stick the bat up your ****.
IMO any CEO can really say whatever they want to sound convincing, as such mutterings are subject to the Disclaimer at the start of the presentation. Forward looking statements are guesses, by definition. For me, a question remains; how much do I trust the management not to finesse the experimental data (which can sometimes be quite easy even if unintentional)? Are the experiments blinded in any way or subject to continuous independent oversight (hello scientific board members) to weed out biases? Will they be published in full? Can the results be reproduced? I have my fingers crossed that all is in safe hands. Science aint easy. DYOR.
CEO said publicly that it won't go bust, so it won't go bust. He also previously said they're going to raise loads of dosh, so they're going to raise loads of dosh. When the CEO makes those statements, they must be taken as fact.
Hi Phil that would put you at the 16th largest shareholder I am at 53 at present. Still have hope things will come good not long to find out
Safe to say it's been attritional. I remain hopeful, but it has been a shambolic investment to this point. Haven't had the stomach to put more in recently, best of luck to those that have. Still got around 200k shares, average perhaps 30 or 40p, massively down. Sign a licencing deal and landscape changes beyond belief - many multiples possible with any sort of respectable licencing terms or asset (hrpc) sale. In the meantime, just nice to see a few blue days.
I remember when Woodford bought in at £5 a share
Sadly I can beat that Allenby, 137.25!!!
Remember when it was over £3!
You are both very lucky I have been in this share over 10years and my break even is 118p. It is the worst share by far that I ever bought.
You lucky bas&&&& etc. 74p BE for me. Haha.
As some are wondering what the reason is for the rise in share price. Yesterday a delayed trade of about 2.4 Million shares appeared after hours. My guess is that Obotritia Capital KGaA has sold it's last lot and is now fully out. They were the seller over the last few months that had caused the drop. I was waiting for them to be out before I added more and it looks like others have done the same, hence the rise.
I can see the share price rising steadily over the next month a positions are taken in anticipation of an update on the in vivo data as promised by Iain in the recent presentation. Iain hinted that the data was looking very good, so I am expecting a very good update. This data will be sufficient to then begin discussions and hopefully sign a licensing deal.
I need 20p to break even on this... Last chance saloon here.
New Edison report.
https://www.edisongroup.com/research/full-steam-ahead-with-customex/32377/
30 May 2023
ReNeuron Group — Full steam ahead with CustomEx
ReNeuron’s FY23 results provide a recap of financial and operational highlights from the period. Following the restructuring announcement in January 2023, the company’s focus rests on its proprietary stem cell-derived exosome platform, CustomEx. In vivo animal studies to validate the platform’s capabilities are ongoing, and ReNeuron plans to release readout data in H2 CY23, which we anticipate could be a key catalyst and generate traction for partnerships. Due to the macroeconomic environment, management is closely monitoring and managing expenses. As of 31 March 2023, the company’s cash balance was £7.2m, which management expects should fund operations into July 2024. While FY23 operating expenses were lower year-on-year and we have reduced future opex projections given the restructuring and guidance, we have also taken a more conservative approach to the long-term assumptions of potential licensing deals to reflect the current macroeconomic (funding and activity) environment. These adjustments and rolling our model forward result in a revised valuation of £29.3m or 51p/share (previously £44.2m or 77p).....